Know Cancer

forgot password

Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis

18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis


- Determine whether the biologic activity of locally advanced breast cancer as measured
by retention of iodine I 124 iododeoxyuridine (IUdR) on positron emission tomography
(PET) scans pre- and postchemotherapy is different between patients whose tumor shrinks
after treatment in comparison to patients whose tumor is stable or continues to grow.

- Demonstrate that incorporation of IUdR into tumor is in the tumor DNA at 24-36 hours
post injection, as documented by tissue analysis and immunohistochemistry and that this
correlates with the subsequent change in tumor dimension and proliferative activity of
the tumor.

- Compare the pre and post treatment results of fludeoxyglucose (FDG) PET scanning and
IUdR PET scanning in the same breast lesions as a basis for assessment of the relative
metabolic change during chemotherapy.

- Further assess the biologic activity of metastatic tumor sites and their changes in
size following chemotherapy to standard parameters that are used to evaluate change in
tumor size, obtained under clinical standard of care for breast cancer, which will
include CT scans as well as bone scans.

- Assess the accuracy of noninvasive measurement of PET measurement of the left
ventricular cardiac chamber clearance of radioactivity as a substitute for arterial
plasma sampling for determining metabolic rates of FDG and IUdR uptake into tumors.

- Evaluate metabolic changes in tumors as they are affected by specific chemotherapy in
comparison to changes in tumor dimensions.

OUTLINE: For this study, the chemotherapy administered for an individual patient is at the
discretion of the patient's primary attending physician. After chemotherapy, the patient is
evaluated for surgical resection of the tumor. If the tumor is unresectable, the patient may
be offered radiation therapy.

The first group of positron emission tomography (PET) scans is performed within 2 weeks
before the first dose of chemotherapy. The second group of PET scans occur no more than 7
weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy.

The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one
iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours
after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45
minutes after FDG infusion.

PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.

Inclusion Criteria


- Histologically confirmed locally advanced breast carcinoma

- Stage T3 T4, N2 or N3 disease

- Hormone receptor status:

- Not specified



- 18 and over


- Male or female

Menopausal status:

- Not specified

Performance status:

- Karnofsky 80-100%


- Not specified


- Not specified


- Not specified


- No history of psychiatric illness that would preclude giving informed consent

- Not pregnant

- Fertile patients must use effective contraception


Biologic therapy

- Not specified


- Not specified

Endocrine therapy

- Not specified


- Not specified


- Not specified

Type of Study:


Study Design:

Primary Purpose: Diagnostic

Principal Investigator

Teresa Ann Gilewski, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

March 1997

Completion Date:

December 2008

Related Keywords:

  • Breast Cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • stage IIIC breast cancer
  • male breast cancer
  • Breast Neoplasms



Memorial Sloan-Kettering Cancer Center New York, New York  10021